```html

Oxalosis – A Complete Patient‑Friendly Guide

Overview

Oxalosis (also called systemic oxalosis) is a rare metabolic disorder in which excess oxalate—a salt of oxalic acid—accumulates in body tissues, especially the kidneys, bones, eyes, heart, and skin. The condition usually results from a severe, lifelong inability to break down oxalate, leading to crystal deposition and organ dysfunction.

Who it affects: Oxalosis can occur at any age, but most cases are identified in childhood or early adulthood because the underlying enzyme deficiency is present from birth. Secondary oxalosis (due to kidney failure or high dietary intake) is more common in adults with chronic kidney disease.

Prevalence: Primary hyperoxaluria (the most common cause of oxalosis) affects roughly 1 to 3 per 1 million people worldwide, although exact numbers are uncertain due to under‑diagnosis. In the United States, the National Institutes of Health (NIH) estimates ~150–200 diagnosed cases, with many more likely undetected.<sup>[1] NIH Rare Diseases Information Center</sup>

Symptoms

Symptoms result from crystal deposition in various organs. Not every patient experiences all of them, and severity can range from mild to life‑threatening.

• Kidney‑related symptoms
  • Recurrent kidney stones (often calcium oxalate)
  • Flank pain or aching
  • Hematuria (blood in the urine)
  • Decreased urine output or progression to chronic kidney disease
• Bone and joint complaints
  • Bone pain, especially in the spine, ribs, or long bones
  • Fragile bones leading to fractures from minor trauma
  • Joint stiffness or swelling from crystal deposits
• Skin manifestations
  • Yellow‑brown papules or nodules (often on the arms, legs, or abdomen)
  • Itching or a burning sensation over lesions
• Eye involvement
  • Conjunctival or corneal deposits causing blurred vision, photophobia
  • In severe cases, glaucoma or retinal damage
• Cardiovascular signs
  • Cardiomyopathy or heart rhythm abnormalities (rare, usually in advanced disease)
• Systemic symptoms
  • Fatigue and generalized weakness
  • Unexplained weight loss
  • Frequent urinary tract infections (UTIs) due to stone fragments

Causes and Risk Factors

Primary (genetic) causes

The most common pathway is primary hyperoxaluria (PH), an inherited autosomal‑recessive disorder that impairs hepatic enzymes responsible for converting glyoxylate to less harmful substances.

• PH type 1 – deficiency of alanine‑glyoxylate aminotransferase (AGXT). Accounts for ~70 % of PH cases.
• PH type 2 – deficiency of glyoxylate reductase/hydroxypyruvate reductase (GRHPR).
• PH type 3 – deficiency of 4‑hydroxy‑2‑oxoglutarate aldolase (HOGA1).

Secondary (acquired) causes

• End‑stage renal disease (ESRD) – kidneys can no longer excrete oxalate, causing systemic buildup.
• High‑oxalate diet (e.g., excessive rhubarb, star‑fruit, spinach, nuts) combined with gut malabsorption (Crohn’s disease, bariatric surgery).
• Vitamin C megadoses – vitamin C is metabolized to oxalate; doses >2 g/day can raise urinary oxalate dramatically.
• Ethylene glycol poisoning – metabolized to oxalic acid, producing acute oxalosis.

Risk factors

• Family history of primary hyperoxaluria or recurrent calcium oxalate stones.
• Chronic kidney disease or dialysis dependence.
• GI conditions that cause fat malabsorption (e.g., short‑bowel syndrome).
• Excessive intake of oxalate‑rich foods or high‑dose vitamin C supplements.

Diagnosis

Because early symptoms overlap with common kidney stone disease, a high index of suspicion is crucial, especially in patients with recurrent stones, early‑onset renal failure, or a positive family history.

Laboratory tests

• Urine oxalate measurement – 24‑hour collection; values >45 mg/24 h are considered elevated.
• Plasma oxalate level – Normal < 5 µmol/L; levels >30 µmol/L strongly suggest systemic oxalosis, especially in renal failure.
• Serum creatinine, eGFR, electrolytes to assess kidney function.
• Genetic testing – targeted sequencing of AGXT, GRHPR, and HOGA1 genes confirms primary hyperoxaluria.<sup>[2] Mayo Clinic</sup>

Imaging studies

• Non‑contrast CT scan – Gold standard for detecting calcium oxalate stones.
• Bone scan or MRI – Shows oxalate deposits in bone and soft tissue.
• Ophthalmologic examination – Slit‑lamp exam for corneal/conjunctival crystals.

Biopsy (rare)

In ambiguous cases, a kidney or skin biopsy examined with polarized light microscopy can reveal characteristic birefringent oxalate crystals.

Treatment Options

Treatment aims to lower oxalate production, enhance its removal, and manage organ damage.

Medical therapies

• Pyridoxine (Vitamin B6) – Effective in ~30 % of PH‑1 patients with specific AGXT mutations; dose 5–20 mg/kg/day.
• Potassium citrate – Alkali therapy reduces stone formation by increasing urinary citrate, which binds calcium.
• Calcium supplements (with meals) – Binds dietary oxalate in the gut, reducing absorption.
• Oral Oxalate‑degrading enzymes (e.g., Oxalobacter formigenes probiotic) – Experimental; early studies show modest reduction in urinary oxalate.
• High‑dose dialysis – Intensive hemodialysis (≥6 h, 6 days/week) can lower plasma oxalate in ESRD patients awaiting transplantation.

Surgical and procedural interventions

• Stone removal – Extracorporeal shock‑wave lithotripsy (ESWL), ureteroscopy, or percutaneous nephrolithotomy as indicated.
• Renal transplantation – Considered curative for PH‑1 when combined with a simultaneous liver transplant (liver provides the missing enzyme). Isolated kidney transplant alone often fails because the metabolic defect persists.
• Liver transplantation – Restores functional AGXT enzyme; indicated for severe PH‑1 when dialysis is insufficient.

Lifestyle and dietary measures

• Restrict dietary oxalate to < 100 mg/day (e.g., limit spinach, nuts, chocolate, tea).
• Maintain adequate hydration – >2.5 L of fluid per day to keep urine output >2 L.
• Avoid vitamin C > 1 g/day.
• Consume calcium (1,000–1,200 mg/day) with meals to bind oxalate.
• Limit animal protein (which can increase urinary calcium and oxalate).

Living with Oxalosis

Managing a chronic, rare disease can be overwhelming. Practical tips help maintain quality of life.

Daily routines

• Track fluid intake with a water‑tracking app; aim for clear or pale‑yellow urine.
• Keep a food diary—many diet‑tracking tools let you flag high‑oxalate items.
• Take prescribed meds (pyridoxine, citrate) at the same time each day to improve adherence.
• Schedule regular follow‑ups (every 3–6 months) with a nephrologist familiar with metabolic stone disease.

Support resources

• Join patient advocacy groups such as the International Primary Hyperoxaluria Consortium for community support.
• Consider genetic counseling for family planning.
• Maintain an updated emergency card noting “Oxalosis – high oxalate levels – avoid vitamin C megadoses.”

Monitoring & self‑care

• Watch for new stone symptoms—pain, hematuria, or fever—and seek prompt evaluation.
• Annual eye exam to detect early ocular deposits.
• Bone health: Vitamin D and bisphosphonate therapy may be recommended if osteoporosis develops.

Prevention

While genetic forms cannot be prevented, many strategies reduce the burden of secondary oxalosis.

• Hydration – The single most effective preventive measure; aim for ≥2 L of urine per day.
• Dietary control – Low‑oxalate diet plus calcium intake with meals.
• Avoid excessive vitamin C – Do not exceed 1 g/day unless prescribed.
• Prompt treatment of gut malabsorption – Manage Crohn’s disease or adjust after bariatric surgery to limit oxalate absorption.
• Regular monitoring in at‑risk families – Early urine oxalate screening for siblings of known PH patients.

Complications

If the disease is left untreated or inadequately controlled, complications can be severe.

• Chronic kidney disease progressing to end‑stage renal disease (ESRD) – Occurs in >50 % of untreated PH‑1 patients before age 30.<sup>[3] Cleveland Clinic</sup>
• Recurrent, obstructive kidney stones – Can cause hydronephrosis, infections, and loss of renal function.
• Bone disease – Osteopenia, fractures, and severe bone pain due to crystal deposition.
• Cardiovascular involvement – Oxalate infiltration of myocardium leading to cardiomyopathy.
• Vision loss – Corneal deposits may necessitate corneal transplantation.
• Systemic infection – Stones can harbor bacteria, leading to recurrent UTIs or sepsis.

When to Seek Emergency Care

References

1. National Institutes of Health (NIH) – Rare Diseases Information Center. “Primary Hyperoxaluria.” Accessed April 2024.
2. Mayo Clinic. “Primary hyperoxaluria.” Patient care information. Updated 2023.
3. Cleveland Clinic. “Kidney stones and metabolic disorders.” Clinical overview, 2022.
4. World Health Organization (WHO). “Guidelines for the management of rare metabolic diseases.” 2021.
5. U.S. Centers for Disease Control and Prevention (CDC). “Kidney stone prevention.” 2023.

```